Skip to main content
Erschienen in: Strahlentherapie und Onkologie 5/2013

01.05.2013 | Literatur kommentiert

Frühe postoperative Strahlentherapie nach radikaler Prostatektomie bei „High-risk“-Prostatakarzinompatienten weiterhin Standard

Langzeitergebnisse der EORTC-Studie 22911

verfasst von: Dr. M. Ehmann, F. Wenz

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 5/2013

Einloggen, um Zugang zu erhalten

Auszug

Bolla M, Poppel H van, Tombal B et al (2012) Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long term results of a randomised controlled trial (EORTC trial 22911). Lancet 380:2018–2027 …
Literatur
1.
Zurück zum Zitat Bolla M et al (2005) Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 366:572–578PubMedCrossRef Bolla M et al (2005) Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 366:572–578PubMedCrossRef
2.
Zurück zum Zitat Bolla M, Poppel H van, Tombal B et al (2012) Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long term results of a randomised controlled trial (EORTC trial 22911). Lancet 380:2018–2027PubMedCrossRef Bolla M, Poppel H van, Tombal B et al (2012) Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long term results of a randomised controlled trial (EORTC trial 22911). Lancet 380:2018–2027PubMedCrossRef
3.
Zurück zum Zitat Siegmann A et al (2011) Dose escalation for patients with decreasing PSA during radiotherapy for elevated PSA after radical prostatectomy improves biochemical progression-free survival: results of a retrospective study. Strahlenther Onkol 187:467–472PubMedCrossRef Siegmann A et al (2011) Dose escalation for patients with decreasing PSA during radiotherapy for elevated PSA after radical prostatectomy improves biochemical progression-free survival: results of a retrospective study. Strahlenther Onkol 187:467–472PubMedCrossRef
4.
Zurück zum Zitat Ost P et al (2009) Adjuvant high-dose intensity-modulated radiotherapy after radical prostatectomy for prostate cancer: clinical results in 104 patients. Eur Urol 56:669–675PubMedCrossRef Ost P et al (2009) Adjuvant high-dose intensity-modulated radiotherapy after radical prostatectomy for prostate cancer: clinical results in 104 patients. Eur Urol 56:669–675PubMedCrossRef
5.
Zurück zum Zitat Wiegel T et al (2009) Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 27:2924–2930PubMedCrossRef Wiegel T et al (2009) Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 27:2924–2930PubMedCrossRef
6.
Zurück zum Zitat Williams MB, Hernandez J, Thompson I (2005) Luteinizing hormone-releasing hormone agonist effects on skeletal muscle: how hormonal therapy in prostate cancer affects muscular strength. J Urol 173:1067–1071PubMedCrossRef Williams MB, Hernandez J, Thompson I (2005) Luteinizing hormone-releasing hormone agonist effects on skeletal muscle: how hormonal therapy in prostate cancer affects muscular strength. J Urol 173:1067–1071PubMedCrossRef
7.
Zurück zum Zitat Stephenson AJ et al (2007) Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 25:2035–2041PubMedCrossRef Stephenson AJ et al (2007) Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 25:2035–2041PubMedCrossRef
8.
Zurück zum Zitat Radiotherapy – Adjuvant Versus Early Salvage (RAVES). ClinicalTrials.gov Identifier: NCT00860652 Radiotherapy – Adjuvant Versus Early Salvage (RAVES). ClinicalTrials.gov Identifier: NCT00860652
9.
Zurück zum Zitat Parker C et al (2007) RADICALS (Radiotherapy and Androgen Deprivation in Combination after Local Surgery). Clin Oncol (R Coll Radiol) 19:67–171 Parker C et al (2007) RADICALS (Radiotherapy and Androgen Deprivation in Combination after Local Surgery). Clin Oncol (R Coll Radiol) 19:67–171
10.
Zurück zum Zitat Triptorelin and radiation therapy in treating patients who have undergone surgery for intermediate-risk stage III or stage IV prostate cancer. ClinicalTrials.gov Identifier: NCT00667069 Triptorelin and radiation therapy in treating patients who have undergone surgery for intermediate-risk stage III or stage IV prostate cancer. ClinicalTrials.gov Identifier: NCT00667069
Metadaten
Titel
Frühe postoperative Strahlentherapie nach radikaler Prostatektomie bei „High-risk“-Prostatakarzinompatienten weiterhin Standard
Langzeitergebnisse der EORTC-Studie 22911
verfasst von
Dr. M. Ehmann
F. Wenz
Publikationsdatum
01.05.2013
Verlag
Springer-Verlag
Erschienen in
Strahlentherapie und Onkologie / Ausgabe 5/2013
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-013-0333-2

Weitere Artikel der Ausgabe 5/2013

Strahlentherapie und Onkologie 5/2013 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.